Promising Triple-Drug cocktail targets tough leukemia mutation
NCT ID NCT06611839
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with acute myeloid leukemia (AML) that has an IDH1 mutation. The goal is to see if this triple therapy can improve remission rates and survival. About 23 participants will receive the treatment, and researchers will monitor safety and effectiveness. This approach builds on earlier promising results in patients who couldn't tolerate standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.